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Abstract: 
Introduction: Polycystic ovary syndrome (PCOS) is an endocrine and reproductive disorder with a prevalence 
ranging from 5% to 13% in women of reproductive age. Aims and objectives: The main objective of the study is to 
analyze the effect of Letrozole for Ovulation Induction in Polycystic Ovary Syndrome in female population.  
Material and methods: This cross sectional study was conducted in DHQ hospital, Narowal during March 2018 to 
December 2018. The data was collected from 100 female patients who visited the OPD of the hospital during their 
diseases. All those female who were suffering from PCOS, included in this study. All cases of infertile women with 
PCOS from 18 to 45 years old were analyzed in this study. All patients underwent letrozole on cycle day 3 for 
consecutive 5 days for up to 5 menstrual cycles. If there was a nonresponse or a poor ovulatory response occurred, 
the dose was increased in subsequent cycles in the either group. The maximum daily dose of letrozole was 7.5 mg. 
Results: The data were collected from 100 female patients. The results showed that patients who received letrozole did 
not exert better outcomes in neither primary endpoint, including live birth. There were not significant differences in 
all adverse events. All the values were expressed in mean and standard deviation.  
Conclusion: It is concluded that induction of ovulation with letrozole in PCOS patients is associated with limited 
number of mature follicles, no adverse effect on endometrial thickness or cervical mucous, and ovulation and 
pregnancy in a significant number of patients. 
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INTRODUCTION: 
Polycystic ovary syndrome (PCOS) is an endocrine 
and reproductive disorder with a prevalence ranging 
from 5% to 13% in women of reproductive age. PCOS 
is the primary cause of hyperandrogenism and oligo-
anovulation at the reproductive age and is often 
associated with infertility 3 and clinical and metabolic 
disorders [1]. 
The prevalence of infertility in women with PCOS 
varies between 70 and 80%. According to the 
American Society for Reproductive Medicine, the 
evaluation of infertility in women with PCOS or other 
causes of subfertility should start after six months of 
attempting pregnancy without success if the couple 
has regular sexual intercourse (2 to 3 times/week) 
without using contraceptive methods [2]. To optimize 
the efficacy of the treatment of infertile women with 
PCOS, evaluations of tubal patency 
(hysterosalpingography or laparoscopy with 
chromotubation) and semen analysis (spermogram) 
are mandatory before deciding on treatment. However, 
tubal patency evaluation may not be necessary prior to 
initiating clomiphene citrate (CC) treatment [3]. 
Notably, if a patient is resistant to this drug and/or 
requires the use of gonadotropins and/or presents with 
other causes of infertility, a tubal patency evaluation 
becomes mandatory prior to initiating the therapeutic 
treatment of infertility [4]. 
Letrozole is an aromatase inhibitor that was used as an 
ovulation inductor in anovulatory infertility women 
with more than 56 mm endometrial thickness. It 
inhibits estrogen production by repressing the enzyme 
aromatase [5]. It has been reported that letrozole can 
inhibit estrogen levels by at least 97% to 99%. The 
other studies also reported that letrozole is effective 
in clomiphene-resistant patients, and also resulted in 
ovulation of 62% cases, and pregnancy of 14.7% 
[6]. Additionally, no adverse events have been 
reported on fetus. However, current data are still 
insufficient to support the idea that letrozole can be 
utilized effectively to treat such condition. Therefore, 
in this retrospective study, we investigated 
the efficacy and safety of letrozole for infertility 
women with PCOS [7]. 
Aims and objectives 
The main objective of the study is to analyze the effect 
of Letrozole for Ovulation Induction in Polycystic 
Ovary Syndrome in female population. 
 
MATERIAL AND METHODS: 
This cross sectional study was conducted in DHQ 
hospital, Narowal during March 2018 to December 
2018. The data was collected from 100 female patients 
who visited the OPD of the hospital during their 
diseases. All those female who were suffering from 
PCOS, included in this study. All cases of infertile 
women with PCOS from 18 to 45 years old were 
analyzed in this study. All patients 
underwent letrozole on cycle day 3 for consecutive 5 
days for up to 5 menstrual cycles. If there was a 
nonresponse or a poor ovulatory response occurred, 
the dose was increased in subsequent cycles in the 
either group. The maximum daily dose 
of letrozole was 7.5 mg. 
 
Statistical analysis: 
All outcome and characteristic values were analyzed 
by using SPSS software (SPSS V.17.0). Continuous 
non-normally value was analyzed by U test, while 
normally variables were performed by t-test. 
Categorical value was conducted by Chi-squared 
test. P <.05 was defined as having a statistical 
significance. 
 
RESULTS: 
The data were collected from 100 female patients. The 
results showed that patients who received letrozole did 
not exert better outcomes in neither primary endpoint, 
including live birth. There were not significant 
differences in all adverse events. All the values were 
expressed in mean and standard deviation.  
Table 01: Analysis of outcomes of letrozole group 
 
Letrozole group  t P value 
Total number of follicles 4.4 ± 0.4 4.3 .042a 
Number of follicles >14 mm 2.1 ± 0.3 6.13 .008a 
Number of follicles >18 mm 2.3 ± 0.1 5.03 .03a 
Pretreatment endometrial thickness (mm) 4.5 ± 0.4 1.41 .52 
Endometrial thickness at hCG (mm) 8.1 ± 0.2 5.44 .021a 
Serum E2 (pg/mL) 255.1 ± 64.2 4.12 .022a 
Serum progesterone (ng/mL) 7.1 ± 0.9 6.33 .024a 
Duration of stimulation (days) 12.1 ± 1.38 4.91 .036a 
Pregnancy/cycle 82/540 (15.1%) 1.33 .72 
Miscarriage/patient 4 (12.1%) 1.73 .43 
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DISCUSSION: 
Comparing letrozole responders and nonresponders 
with regard to clinical and laboratory characteristics, 
there were no significant differences in BMI, waist or 
hip circumference, waist/hip ratio, hirsutism, LH, 
FSH, or LH/FSH ratio [8]. Thus, letrozole can be 
given to all patients with CC resistance, because its 
efficacy is not limited to a specific abnormality. 
Achieving weight reduction is difficult, particularly as 
the metabolic status of patients with PCOS conspires 
against weight loss [7]. Letrozole can be used in 
patients with hirsutism, and there is no need to add 
dexamethasone to reduce adrenal androgen 
production. Dexamethasone can worsen diabetic 
tendencies and as a result it may not be a suitable 
treatment for patients with diabetes, insulin resistance, 
or glucose intolerance, conditions present in many 
PCOS patients (3). Letrozole can be used in case of 
high LH without the need to add oral contraceptives 
for pretreatment suppression of LH. Oral 
contraceptive pills exacerbate insulin resistance. Many 
PCOS patients are overweight, and obesity is a relative 
contraindication to oral contraceptive pills [9]. 
On the other hand, regarding the positive effect of 
letrozole in producing FSH sensitivity and satisfactory 
E2 elevation (at normal physiological levels), it can 
have better therapeutic effects in infertile females. In 
addition, because serum clearance of letrozole is faster 
than clomiphene citrate and does not lead to a decrease 
in the estrogen receptors, it is probable that letrozole 
does not produce deleterious effects similar to that 
found with clomiphene citrate on the endometrium, 
although it can lead to pregnancy at similar or even 
higher rates [10]. 
CONCLUSION: 
It is concluded that induction of ovulation with 
letrozole in PCOS patients is associated with limited 
number of mature follicles, no adverse effect on 
endometrial thickness or cervical mucous, and 
ovulation and pregnancy in a significant number of 
patients. Induction with letrozole does not seem to 
depend on age, period of infertility, BMI, waist 
circumference, LH, FSH or LH/FSH ratio. 
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